# Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)

> **NCT02631863** · PHASE2 · COMPLETED · sponsor: **Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Cervical Intraepithelial Neoplasia
- Low-Grade Squamous Intraepithelial Lesions
- Papillomavirus Infections

## Interventions

- **DRUG:** Aminolaevulinic acid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02631863
- **Lead sponsor:** Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-22
- **Primary completion:** 2018-11-24
- **Final completion:** 2018-11-24
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02631863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02631863, "Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02631863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*